Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Alzamend Neuro , Inc. (NASDAQ:ALZN), a biopharmaceutical company focused on developing treatments for neurological disorders and diseases, has announced amendments to its corporate bylaws and the introduction of a new series of convertible preferred stock. With a current market capitalization of just $4.04 million and a healthy current ratio of 3.8, the company maintains more cash than debt on its balance sheet, according to InvestingPro data. The changes were disclosed in a recent filing with the Securities and Exchange Commission.
On Monday, the Board of Directors of Alzamend Neuro approved the First Amendment to the Amended and Restated Bylaws of the Company, effectively immediately. The amendment primarily modifies the quorum requirement for stockholder meetings. Previously, a majority of the outstanding capital stock entitled to vote was necessary to establish a quorum. With the new amendment, the requirement has been reduced to 35% of the outstanding capital stock entitled to vote, either in person or by proxy.
In addition to the bylaws amendment, Alzamend Neuro has filed a Certificate of Designations with the Secretary of State of Delaware to create its Series C Convertible Preferred Stock. This action follows the company’s agreement with a sophisticated investor to exchange shares of the company’s Series A Convertible Preferred Stock for an equal number of shares of Series C Preferred Stock and to sell up to 500 shares of the Series C Preferred Stock to the investor.
The Certificate of Designation details the preferences, voting powers, limitations, and other terms of the Series C Preferred Stock. This strategic move aims to enhance the company’s financial flexibility and support its ongoing development projects.
The company has provided the full text of the First Amendment and the Certificate of Designation as exhibits to the SEC filing. These documents offer comprehensive details on the amendments and the rights associated with the new Series C Preferred Stock. Despite trading near its 52-week low, InvestingPro’s Fair Value analysis suggests the stock may be undervalued at current levels, though investors should note the company’s challenging financial metrics and negative EBITDA of -$5.78 million in the last twelve months.
This announcement is based on the information contained in the SEC filing by Alzamend Neuro, Inc. and does not include any additional analysis or commentary.
In other recent news, Alzamend Neuro, Inc. has finalized an agreement for the sale and exchange of equity securities, potentially amounting to $5 million, as detailed in an SEC filing. This deal involves the exchange of Series A Convertible Preferred Stock for Series C Convertible Preferred Stock and the sale of additional Series C shares, including warrants for common stock. These securities offer a 15% annual dividend and preferential rights in case of liquidation. Additionally, Alzamend Neuro has announced the completion of a specialized head coil developed by Tesla (NASDAQ:TSLA) Dynamic Coils BV, which will be used in upcoming Phase II clinical trials. These trials will compare the pharmacokinetics of Alzamend’s AL001 with traditional lithium carbonate for neurological and psychiatric conditions. The head coil is designed for high-resolution brain imaging, aiming to optimize lithium dosages for conditions like Alzheimer’s and bipolar disorder. Alzamend’s collaboration with Massachusetts General Hospital will oversee these trials, which could eliminate the need for therapeutic drug monitoring of lithium. The company anticipates that this technology will enhance the safety and efficacy of lithium treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.